SCHEMBL7123419

SCHEMBL7123419

NS(=O)(=O)c1ccccc1Sc1ccc(C(=O)N[C@@H]2C[C@H]3CC[C@@H]2N3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.39
CA1 P00915 6/20 0.38
CA2 P00918 4/20 0.38
CA9 Q16790 4/20 0.38
CA12 O43570 2/20 0.38
CA4 P22748 2/20 0.38
CA6 P23280 2/20 0.38
CA5A P35218 2/20 0.38
CA7 P43166 2/20 0.38
CA13 Q8N1Q1 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA5B Q9Y2D0 2/20 0.38
EZH2 Q15910 1/20 0.35
PSMD14 O00487 1/20 0.33
USP2 O75604 1/20 0.33
PLA2G1B P04054 1/20 0.33
ALPL P05186 1/20 0.33
POLB P06746 1/20 0.33
MMP2 P08253 1/20 0.33
ALPI P09923 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7117999 0.86 CHRNA7 (0.42) CHRNA7EZH2KMT2ATDP1ALDH1A1
SCHEMBL7125311 0.85 CHRNA7 (0.42) CHRNA7EZH2TDP1ALDH1A1MAPT
SCHEMBL7115015 0.84 CA2 (0.42) CHRNA7CA1CA2CA9CA12
SCHEMBL7116417 0.84 SIRT1 (0.46) CHRNA7EZH2TDP1MAPTHTR3E
SCHEMBL7117164 0.83 CHRNA7 (0.42) CHRNA7EZH2TDP1MAPTHTR3E
SCHEMBL7127524 0.83 CHRNA7 (0.55) CHRNA7EZH2KMT2AALDH1A1HPGD
SCHEMBL7125119 0.82 ALDH1A1 (0.48) CHRNA7EZH2POLBKMT2ATDP1
SCHEMBL7120626 0.82 CHRNA7 (0.40) CHRNA7EZH2TDP1ALDH1A1HPGD
SCHEMBL7224373 0.82 CA12 (0.31) CHRNA7CA1CA2CA9CA12
SCHEMBL7120751 0.81 CHRNA7 (0.41) CHRNA7CA1CA2CA9CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 CHRNA7 397/4885CA1 4282/4885CA2 3875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.